Algeta Reports Positive Headline Phase II Data on Pain Palliation With ...(erations and the financial condition ofA...),Health

Date:8/28/2008

erations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products.

For further information, please contact:

Dr. Thomas Ramdahl, CEO,

+47-23-00-79-90 / +47-913-91-458 (mob);

0ystein Soug, CFO,

+47-23-00-79-84 / +47-906-56-525 (mob),

post@algeta.com;

For international enquiries:

Dr. Mark Swallow / David Dible,

Citigate Dewe Rogerson,

+44(0)207-638-9571,

mark.swallow@citigatedr.co.uk

'/>"/>

SOURCE Algeta Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials